RARE

Ultragenyx Pharmaceutical Inc. $13.61 1M -48.4% 3M -44.1% YTD -42.3% as of 2026-09-14
+Watchlist

next ticker · + or scroll to zoom · pan · 0 reset

▲ buy   ▼ sell  ·  size ≈ trade size  · earnings beat miss  ·  ring before open after close  ·  moving averages · click the buttons above to hide them

Model view — historical tendencies for the days ahead, not a forecast
Next 1 day
+0.1%
Next 1 week
-0.5%
Next 1 month
-0.9%
Seasonality
Weak window historically
Next 30 days (to Oct 15): -4.5% median, 18% of the last 11 years finished up.
20-year seasonality chart →
Mean reversion
Deeply oversold — RSI(2) at 4
RSI(2) under 15 is oversold (this name has historically bounced); over 85 is overbought. Its dip-buy edge in history is +0.10%/day.
Mean-reversion stats →
1-month breakdown — Market · β 1.20 -0.6% · Seasonal tilt (11y) -0.3%
$88M/day volume 81% volatility -56% 1-year
52-week range · 0% of the way up · -66% from the high
$13.60$39.89

Congressional trades in RARE Full tracker →

1 member · 4 buys / 0 sells · $4K–$60K disclosed · latest filing Apr 7, 2026.

BUY GC Gilbert Cisneros · traded Mar 3, 2026 $1K–$15K
BUY GC Gilbert Cisneros · traded Feb 18, 2026 $1K–$15K
BUY GC Gilbert Cisneros · traded Aug 8, 2025 $1K–$15K
BUY GC Gilbert Cisneros · traded Jul 15, 2025 $1K–$15K

Earnings Full history →

Next report 2026-11-03 (Tuesday, after close, in 49 days) · EPS est. -0.66.

1-day std dev
5.6%
Finished up
39%
Biggest pop
+14.3%
Biggest drop
-13.4%

Standard deviation of the close-to-close move over the last 51 reports. History, not a forecast.

Data from the U.S. House Clerk and FINRA, plus end-of-day prices. Not investment advice.